Clinical Trial: Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1

U.S., Sept. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07797283) titled 'Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1' on Aug. 26.

Brief Summary: The purpose of this study is to evaluate INCB123667 in Combination With Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Participants With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Overexpressing Cyclin E1.

Study Start Date: Dec. 01, 2026

Study Type: INTERVENTIONAL

Condition: Ovarian Cancer

Intervention: DRUG: INCB123667

INCB123667 will be administered at the protocol defined dose.

DRUG: Bevacizum...